Moderna Stock

Moderna OCF/Debt

The Operating Cash Flow to Debt Ratio of Moderna (MRNA) as of Aug 10, 2026 is -307.05 %. In the previous year, Operating Cash Flow to Debt Ratio was -4,845.16 % — a change of -93.66% (higher).

OCF/Debt

-307.05 %

YoY

-93.66%

Last updated:

Operating Cash Flow to Debt Ratio of Moderna is 2026 -307.05 % . Operating Cash Flow to Debt Ratio of Moderna was 2025 -4,845.16 % . It decreases by -93.66% higher compared to the previous year.
Access this data via the Eulerpool API

Moderna Stock analysis

What does Moderna do? Moderna Inc is a biotechnology company from the USA that specializes in the development of therapies and vaccines based on mRNA technology. The company was founded in 2010 by a group of researchers led by Noubar Afeyan and is headquartered in Cambridge, Massachusetts. Moderna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moderna stock

Operating Cash Flow to Debt Ratio of Moderna is -307.05 % in 2026.

Operating Cash Flow to Debt Ratio of Moderna changed from -4,845.16 % to -307.05 %, representing a -93.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Moderna since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Moderna with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Moderna

All Key Metrics — Moderna